Wainright Presentation

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Posts: 430
Joined: Fri Jul 20, 2018 5:13 pm

Wainright Presentation

Post by biopearl123 » Mon Sep 14, 2020 6:53 pm

Today's (pending as of now) Wainright presentation contains a slide indicating an "unchecked box" relating to the upcoming ASH meeting in December (they will almost certainly be virtual). The usual accept/reject dates for abstracts is early October. Yet we see an indication that Geron data updates are anticipated. Since Geron "signed up" for Wainright about a week ago, they must have known then,(or else they were very confident). We have seen the very strict regulations regarding information release re scientific meetings to allow for acknowledging acceptance of posters and oral presentations, just no further info beyond that until the abstract titles are released in early November. If indeed Geron has received notification this early it might indicate that the kind of special attention paid to abstracts of high importance has occurred. Given the unprecedented OS data in MF, and the unprecedented TI datain MDS, in a drug with an entirely unique class of action, perhaps Geron will get the recognition accorded to a plenary. presentation, we shall see. Regards to all, bp

Posts: 152
Joined: Sun Apr 03, 2016 11:27 pm

Re: Wainright Presentation

Post by cheng_ho » Mon Sep 14, 2020 8:19 pm

I'm sure Geron will get into ASH. Even if the trial results were negative, they're still human trial results on a new MOA, so are important either way.

Post Reply